Ergomed plc Results of 2022 Annual General Meeting (4909O)

TIDMERGO

RNS Number : 4909O

Ergomed plc

10 June 2022

PRESS RELEASE

Results of 2022 Annual General Meeting

Guildford, 10 June 2022: Ergomed plc (AIM: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces the results of voting on the resolutions put to shareholders at its Annual General Meeting ("AGM") held earlier today. All Resolutions were duly passed.

Details of the voting by way of a poll at the AGM in respect of each resolution are shown in the table below:

 
 Resolution          R esolution          Votes for      Votes     Abstentions 
   number                                               against 
     1                Accounts            40,070,518       0        1,492,956 
             --------------------------  -----------  ----------  ------------ 
     2            Reappoint auditor       41,493,555    69,125         794 
             --------------------------  -----------  ----------  ------------ 
     3          Reappoint John Dawson     41,454,634    107,895        945 
             --------------------------  -----------  ----------  ------------ 
     4          Reappoint Mark Enyedy     34,200,041   7,362,488       945 
             --------------------------  -----------  ----------  ------------ 
     5        Reappoint Michael Spiteri   32,439,508   9,123,278       688 
             --------------------------  -----------  ----------  ------------ 
     6            Allot securities        39,399,013   2,163,803       658 
             --------------------------  -----------  ----------  ------------ 
     7           Pre-emption rights       39,808,724   1,754,493       257 
             --------------------------  -----------  ----------  ------------ 
     8           Pre-emption rights       39,699,675   1,863,542       257 
             --------------------------  -----------  ----------  ------------ 
              Amendment to Articles of 
     9         Association                41,563,066       0           408 
             --------------------------  -----------  ----------  ------------ 
 

The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com

Ergomed's Board engage with the Company's shareholders and other stakeholders to understand their views. Whilst all resolutions were passed, shareholders representing over 20% of votes cast voted against Resolution 5 and the Board will re-engage with them to better understand their position.

ENDS

Enquiries :

Ergomed plc Tel: [phone]

Dr Miroslav Reljanović (Executive Chairman)

Richard Barfield (Chief Financial Officer)

Keith Byrne (Senior Vice-President, Capital Markets & Strategy)

Numis Tel: [phone]

Freddie Barnfield / Euan Brown (Nominated Adviser)

James Black (Broker)

Peel Hunt LLP Tel: [phone]

James Steel / Dr Christopher Golden

   Consilium Strategic Communications                                       Tel: [phone] 

Chris Gardner / Matthew Neal [e-mail]

Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGEAEKEFFPAEFA

(END) Dow Jones Newswires

June 10, 2022 06:21 ET (10:21 GMT)